← Back
Data updated: Jul 17, 2026
EASTMAN KODAK
Specialty Pharmaceuticals
EASTMAN KODAK is a specialty pharmaceutical company with 5 FDA-approved products.
1952
Since
5
Drugs
-
Trials
0
New Drugs (2yr)
EASTMAN KODAK's Key Drugs
EASTMAN KODAK's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
EASTMAN KODAK's Recent FDA Approvals
New NDA/BLA approvals for EASTMAN KODAK over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
EASTMAN KODAK's Therapeutic Areas
Disease areas where EASTMAN KODAK has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
EASTMAN KODAK Pipeline Snapshot
Active clinical trials for EASTMAN KODAK across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1952-09-19
- Latest
- 2001-09-17
- Applications
- 3